Modified Enterococcus Pore-Forming Toxins for Selective MHC-I Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack effective methods to harness the therapeutic potential of bacterial toxins, particularly those produced by Enterococci species, which are known for their antibiotic resistance and virulence, and there is a need to understand their specificity and receptors to develop targeted therapeutic applications.
Innovation Solution
Characterization of uncharacterized β-barrel pore-forming toxins (Epx) from Enterococci species, identifying HLA-I as a receptor, and developing modified Epx polypeptides for use in nanopores, immunogenic compositions, and therapeutic applications, including vaccines and adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacterial toxins are used for therapeutic applications, then therapeutic potential is improved, but toxicity and safety concerns worsen
Solution Approach 1:
The patent converts the harmful cytotoxic activity of Epx toxins into a beneficial therapeutic effect by using the toxins to selectively kill immune cells with detrimental MHC class I activity. The modified Epx polypeptides retain their pore-forming capability to induce cell death, but are redirected to target pathological cells rather than healthy cells, thus converting a harmful toxin into a therapeutic agent for treating cancer, autoimmune diseases, and infections.
Solution Approach 2:
The patent modifies the Epx polypeptide sequence to change its specificity and reduce off-target effects. By introducing amino acid substitutions (e.g., K50E, K50A, K56E, K56A) and using variants with at least 85-95% identity to wild-type sequences, the toxin's binding affinity and cellular specificity are altered to enhance therapeutic index while maintaining cytotoxic activity against target cells.
2Manufacturing precision
If modified Epx polypeptides are developed for targeted therapy, then treatment specificity is improved, but complexity of development worsens
Solution Approach 1:
The patent segments the Epx toxin development into distinct components: wild-type Epx polypeptides (SEQ ID NOs: 1-8) as the base structure, modified variants (SEQ ID NOs: 9-25) with specific amino acid changes for enhanced specificity, and different signal sequence options (SEQ ID NOs: 26-33) for targeted delivery. This segmentation allows systematic optimization of each component independently while maintaining the overall therapeutic framework.
3Adaptability or versatility
If Epx toxins are used to block MHC class I activity, then immune evasion capability is improved, but risk of autoimmune responses worsens
Solution Approach 1:
The modified Epx polypeptides act as intermediaries that selectively bind to and block MHC class I molecules on pathological cells, preventing detrimental immune responses without triggering autoimmune reactions. The toxins serve as mediators between the immune system and pathological cells, modulating immune activity by inhibiting MHC class I-mediated immune evasion mechanisms in cancer and autoimmune contexts while maintaining safety through controlled specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified Epx polypeptides can induce immune responses, block MHC class I activity, and treat diseases associated with detrimental MHC class I activity, providing therapeutic and prophylactic options for conditions like cancer, autoimmune diseases, and infections.
Implementation Method 1
the present application discloses a nanopore comprising the isolated Epx polypeptide
Data Source
AI summary
The present application describes in part isolated and modified Enterococci toxin (Epx) polypeptides, immunogenic compositions comprising Exp polypeptides, nanopores formed by Epx polypeptides, apparatus comprising Epx nanopores, and methods of use thereof.